These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 38364363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 4. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z, Wu Q, Li W, Li P, Huang L, Wang T, Zhou Q.
    Lung Cancer; 2023 Dec 01; 186():107386. PubMed ID: 37922771
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
    Li Y, Lu S, Yao P, Huang W, Huang Y, Zhou Y, Yuan Y, Cheng S, Wu F.
    Medicine (Baltimore); 2024 Jan 19; 103(3):e36992. PubMed ID: 38241569
    [Abstract] [Full Text] [Related]

  • 13. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A.
    Clin Lung Cancer; 2021 Jan 19; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract] [Full Text] [Related]

  • 14. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
    Bai H, Han Y, Niu Y, Zhang M.
    Zhongguo Fei Ai Za Zhi; 2021 Aug 20; 24(8):598-604. PubMed ID: 34344501
    [Abstract] [Full Text] [Related]

  • 15. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec 20; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 16. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 17. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
    Fang L, Ding G, Wang M, Ye Y, Yan X, Ding P, Wang J, Zhang Y.
    Medicine (Baltimore); 2022 Aug 26; 101(34):e30255. PubMed ID: 36042596
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L, Wang X.
    Thorac Cancer; 2022 Feb 26; 13(4):637-642. PubMed ID: 34964276
    [Abstract] [Full Text] [Related]

  • 19. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY.
    Lung Cancer; 2020 Apr 26; 142():59-62. PubMed ID: 32114282
    [Abstract] [Full Text] [Related]

  • 20. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D, Xu X, Wen J, Zhang C, Fan M.
    Lung Cancer; 2021 Oct 26; 160():32-35. PubMed ID: 34391065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.